Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Fennec Pharmaceuticals Inc

FENC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$11.71

▲ +2.72%

Market Cap $410.64M · Vol 54.86K

Key Metrics

P/E Ratio

N/A

FWD: 16.20

Market Cap

$410.64M

Small Cap

Div Yield

N/A

EPS Growth

+206.29%

YoY

RSI (14)

59.60

Momentum

Beta

1.07

vs Market

52W High

$13.25

11.62% below

52W Low

$5.65

107.26% above

Volume

54.86K

Avg 60.55K

P/B

7.42

Price-to-book

ROE

N/A

Return on equity

Free Float

80.36%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Fennec Pharmaceuticals Inc (FENC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FENC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.35%

+17.22%

+17.93%

+32.02%

YTD

+52.08%

+35.38%

+42.80%

+46.56%

Financials & Valuation

TTM · Annual

Total Revenue	$44.64M
Net Income	$-9,741,000.00
Revenue Growth (YoY)	+85.18%
Gross Margin	91.57%
Operating Margin	-14.07%
Net Profit Margin	-21.82%
ROE	N/A
ROA · ROIC	-16.68% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	16.20
PEG Ratio	N/A
P/S	4.93
P/B	7.42
P/FCF	N/A
EPS Growth	+206.29%
Outstanding Shares	35.07M

Technical Indicators

50-Day SMA	$10.60
200-Day SMA	$8.47
RSI (14)	59.60
Beta	1.07
52-Week High	$13.25
52-Week Low	$5.65

Volume Today	54.86K
Avg Daily Volume (30D)	60.55K
Relative Volume	0.91x
Volatility (10D)	48.32
Volatility (30D)	70.85
Free Float	80.36%

Analyst Consensus

BUY

Current Price $11.71

Mean Target $17.67

52W Low$5.65 52W High$13.25

Current

Target

$5.65 $13.25

Current Analyst target

+50.87% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S69M23

ISINCA31447P1009

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.